Alnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 52-Week High at $226.62

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Rating)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $226.62 and last traded at $208.28, with a volume of 269293 shares traded. The stock had previously closed at $141.97.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ALNY. Guggenheim lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, June 27th. HC Wainwright boosted their target price on shares of Alnylam Pharmaceuticals from $400.00 to $430.00 in a research note on Monday, May 2nd. BMO Capital Markets boosted their target price on shares of Alnylam Pharmaceuticals from $166.00 to $192.00 and gave the company a “market perform” rating in a research note on Thursday. Chardan Capital boosted their target price on shares of Alnylam Pharmaceuticals from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Cantor Fitzgerald started coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 12th. They set a “neutral” rating and a $175.00 target price for the company. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $225.75.

Alnylam Pharmaceuticals Stock Up 5.7 %

The firm has a market cap of $26.89 billion, a price-to-earnings ratio of -27.42 and a beta of 0.74. The firm’s fifty day moving average is $143.40 and its two-hundred day moving average is $147.42. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.76 and a quick ratio of 3.62.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.67). The company had revenue of $224.80 million during the quarter, compared to analyst estimates of $256.06 million. Alnylam Pharmaceuticals had a negative return on equity of 204.18% and a negative net margin of 110.91%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.61) EPS. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.7 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Tolga Tanguler sold 1,754 shares of the company’s stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $150.00, for a total value of $263,100.00. Following the completion of the sale, the executive vice president now owns 1,754 shares of the company’s stock, valued at $263,100. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.40% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ALNY. UMB Bank N A MO acquired a new stake in Alnylam Pharmaceuticals in the 1st quarter valued at about $28,000. FSB Premier Wealth Management Inc. acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $30,000. KRS Capital Management LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $33,000. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $37,000. Finally, CKW Financial Group lifted its holdings in Alnylam Pharmaceuticals by 50.0% in the 1st quarter. CKW Financial Group now owns 300 shares of the biopharmaceutical company’s stock valued at $51,000 after acquiring an additional 100 shares during the last quarter. 92.39% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.